RxDoctor Payments DataLook up a doctor →

Jacek Zajac, MD

Endocrinology, Diabetes & Metabolism · Lombard, ILNPI 1396817912

Payments from drug & device makers

$26,127in general payments, 2019–2025

Across 1,425 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$3K
  • Novo Nordisk$2K
  • Mannkind Corporation$2K
  • AstraZeneca$2K
  • Corcept Therapeutics$1K
  • Xeris Pharmaceuticals, Inc.$1K
  • plus $14K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC166$3,133
Novo Nordisk159$2,163
Mannkind Corporation102$2,100
AstraZeneca59$1,604
Corcept Therapeutics68$1,369
Xeris Pharmaceuticals, Inc.64$1,285
Dexcom, Inc.64$1,235
Boehringer Ingelheim68$1,133
Sanofi-aventis U.S. LLC53$1,046
Amarin Pharma, Inc.60$966
Bayer45$904
Recordati_rare_diseases_inc.49$899
Amgen40$734
Radius Health, Inc.31$537
AbbVie27$492
Merck37$490
Medtronic(2 entities)25$418
Amneal Pharmaceuticals LLC21$390
Antares Pharma, Inc.24$374
Insulet Corporation20$362
Tandem Diabetes Care, Inc.21$344
Aimmune Therapeutics, Inc.26$307
Abbott19$298
IBSA Pharma Inc.17$278
Novartis11$222
Ascensia Diabetes Care US Inc.7$208
Johnson & Johnson9$208
BETA Bionics, Inc.10$202
Sequel Med Tech, LLC9$163
EUSA Pharma (US) LLC7$155
Takeda Pharmaceuticals U.S.A., Inc.6$143
Verity Pharmaceuticals Inc.4$141
Ascendis Pharma Endocrinology Inc7$139
Valeritas, Inc.10$133
Embecta Corp.6$125
Cequr Corporation2$123
Zealand Pharma US, Inc.5$113
Amryt Pharma Holdings Ltd5$107
Astellas Pharma US Inc5$101
Shire North American Group Inc6$95
Amphastar Pharmaceuticals, Inc.4$74
Kowa Pharmaceuticals America, Inc.5$72
Intuity Medical Inc5$72
Chiesi USA, Inc.3$66
Esperion Therapeutics, Inc.4$62
Madrigal Pharmaceuticals3$61
Arbor Pharmaceuticals, Inc.3$55
GSK3$51
Lifescan, Inc.3$47
Ultragenyx Pharmaceutical Inc.2$46
Kyowa Kirin, Inc.2$45
BD2$40
Halozyme Inc2$38
Theracosbio, LLC3$35
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$33
Acella Pharmaceuticals, LLC1$25
Pfizer1$22
Ipsen Biopharmaceuticals, Inc1$16
Regeneron Healthcare Solutions, Inc.1$13
Vistapharm, Inc.1$12

How this compares

$26,127 in reported general payments places this provider in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

See all endocrinology, diabetes & metabolism providers in Illinois →

Medicare billing

Part B allowed, 2024
$140,054
Medicare patients
444
Services billed
1,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Lombard

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →